Effectiveness and Acceptability of Insertable Devices for Obstetric Fistula Management
- Conditions
- Obstetric FistulaFistula, UrinaryFistulaFistula, Vaginal
- Interventions
- Device: CupDevice: Cup+
- Registration Number
- NCT05444504
- Lead Sponsor
- University of California, San Francisco
- Brief Summary
The investigators propose a clinical trial and nested qualitative study to 1) quantify the effectiveness of an insertable vaginal cup to manage fistula urinary incontinence, 2) examine user and implementer acceptability, and 3) quantify fistula management cost. Two intervention models will be compared among women awaiting fistula surgery or whose surgery was unsuccessful: 1) a vaginal cup ('cup'), and 2) the cup attached via rubber tubing to a leg-secured urine collection bag ('cup+') for greater urine holding capacity.
- Detailed Description
Obstetric fistula is a traumatic maternal morbidity resulting in severe urinary incontinence that increases stigma and reduces quality of life. The estimated two million women with fistula, most in sub-Saharan Africa, face substantial multi-level barriers to surgical repair. Women need an acceptable non-surgical option for therapeutic management of fistula-related urinary incontinence, yet no non-surgical standard of care exists. Use of an insertable silicone vaginal cup has great potential for fistula management; it is effective for menstrual management and efficacious at reducing short-term fistula urinary leakage.
The investigators propose a clinical trial and nested qualitative study to 1) quantify the effectiveness of an insertable vaginal cup to manage fistula urinary incontinence, 2) examine user and implementer acceptability, and 3) quantify fistula management cost. Two intervention models will be compared among women awaiting fistula surgery or whose surgery was unsuccessful: 1) a vaginal cup ('cup'), and 2) the cup attached via rubber tubing to a leg-secured urine collection bag ('cup+') for greater urine holding capacity. Using a cross-over design for efficiency, 100 participants will be randomized to one of two sequences of leaking freely, cup, and cup+ at fistula centers in Ghana, Kenya, and Uganda and observed for four days (total observations=400). Each treatment (cup, cup+ or leaking freely) is used for 24h for day and night use, then crossover. Data are captured through self-report and clinical checklist. On day 4, participants are re-randomized to use cup or cup+ at home for 3 months. Acceptability assessment is informed by implementation and health behavior theory.
Aim 1. To quantify the effectiveness and comparative effectiveness of the cup and cup+. The trial will compare objective and patient-reported measures of effectiveness of the cup and cup+ to leaking freely and of the cup to the cup+. Short-term assessment will be objective (urinary leakage; 8, 24hrs), long-term assessment will be patient-reported (QoL; 1-3 months).
Aim 2. To examine acceptability of cup and cup+. User and implementer acceptability will be assessed using a sequential explanatory mixed-methods design. Acceptability among trial participants will be measured longitudinally (1-3 months). User and implementer acceptability will be examined within in-depth interviews of selected trial participants (n\~30) at 3 months and potential implementers (ob/gyns, midwives/nurses, community health workers, n\~20).
Aim 3. To explore the material and opportunity costs to non-surgical fistula management. Surveys and time motion study among trial participants at facility and community will estimate direct and indirect costs of fistula management from a patient perspective. The long-term goal of the proposed work is to overcome barriers to comprehensive fistula care and increase quality of life through an acceptable, non-surgical option for therapeutic management of fistula.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- Female
- Target Recruitment
- 100
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Group 1 Cup 24 hours of use each of leaking freely, leaking freely, cup, and then cup+ Group 1 Cup+ 24 hours of use each of leaking freely, leaking freely, cup, and then cup+ Group 2 Cup 24 hours of use each of leaking freely, cup, cup+, and then cup Group 2 Cup+ 24 hours of use each of leaking freely, cup, cup+, and then cup
- Primary Outcome Measures
Name Time Method Mean change in volume of observed urine leakage baseline to 6 hours Urine leakage will be measured in mL using pad weight
- Secondary Outcome Measures
Name Time Method Mean change in volume of perceived urine leakage baseline vs. 6 hours, 24 hours,1 month, 2 months and 3 months Perceived urine leakage will be measured by the International Consultation on Incontinence Questionnaire SF (ICIQ-SF). This score ranges from 0-21 with higher scores indicating greater incontinence.
Mean change in WHO Quality of Life BREF (WHOQOL-BREF) score baseline vs. 24 hours, 1 month, 2 months and 3 months Quality of life will be measured using the WHOQOL-BREF. The score ranges from 0-100 with higher scores indicating higher quality of life.
Mean change in fistula-related stigma scale baseline vs. 1 month, 2 months and 3 months Stigma will be measured using the fistula-related stigma scale, and enacted and internalized subscales. This score ranges from 0-100 with higher scores indicating higher stigma.
Mean change in fistula management costs over time baseline vs. 1 month, 2 months, and 3 months Fistula management costs will be calculated by combining the total material costs and lost wages in Ghanaian Cedi (local currency) over time. Time in minutes will inform calculations of lost wages using prevailing wage rates for the study population. The mean change in cost will be from baseline to 3 months.
Mean change in sleep satisfaction using the WHO sleep index baseline vs. 1 month, 2 months, and 3 months Sleep satisfaction using the adapted WHO sleep index. The score ranges from 1-5 where 1 is least satisfied and 5 is very satisfied.
Mean change in Coping Orientation to Problems Experienced Inventory (BRIEF) Coping scale baseline vs. 1 month, 2 months, and 3 months Coping will be measured using the modified BRIEF Coping scale. The score ranges from 0-100 with higher scores indicating better coping.
Mean change in perceived empowerment over time baseline vs. 1 month, 2 months, and 3 months Empowerment change in the proportion of users across physical mobility, participation in income-generating activities, bodily autonomy, household decision making, reproductive autonomy, and social participation. Individual measures will be captured using a scale of 1-5, with 1 indicating lower empowerment and 5 higher.
Changes in perceived safety over time baseline vs. 6 hours, 24 hours, 1 month, 2 months, and 3 months change in the proportion of users who report any adverse events with use of the intervention model at 1, 2, and 3-month follow up
Changes in user acceptability of the intervention over time 6 hours vs. 24 hours, 1 month, 2 months, and 3 months Proportion of users who report the intervention as acceptable measured across domains including easy to insert, remove, clean, comfortable to wear, interference with activities, perceived efficacy, self-efficacy, intent to use, and reported using a mean acceptability scale (based on composite score of acceptability items) regarding the intervention model. Standardized range will be 0-100, with higher values meaning greater acceptability and lower values lower acceptability.
Changes in post-fistula repair reintegration scale baseline vs. 1 month, 2 months, and 3 months Reintegration will be measured using the post-fistula repair reintegration scale and subdomains comfort with relatives, relationship, general life satisfaction, family needs, and social engagement. The score ranges from 0-100 with higher scores indicating higher reintegration/functional status.
Trial Locations
- Locations (3)
Mercy Women's Catholic Hospital
🇬ðŸ‡Mankesim, Ghana
Tamale Fistula Center
🇬ðŸ‡Tamale, Ghana
Gynocare Women's and fistula hospital
🇰🇪Eldoret, Kenya